TP53 and acute myeloid leukemia: Kaplan–Meier analysis showed significantly shorter OS among MK AML TP53 Mut compared to the MK AML TP53 WT group in the study (median OS, 3.9 versus 9.2 months, p = 0.002) (Figure 2C).